Raúl Martínez Fernández

A study conducted in South Korea collected data from more than 410,000 smokers over an average of nine years. The analyses indicate that the risk of developing Parkinson's disease in those who quit smoking during that period was about 60% higher than in those who continued to smoke; however, their risk of death was lower. According to the researchers, who emphasise that the study does not prove that smoking prevents Parkinson's disease, smoking ‘remains one of the leading causes of preventable death and contributes to the development of heart disease, cancer and chronic lung disease. The health benefits of quitting smoking remain substantial and clear.’ The results are published in Neurology.

A monoclonal antibody called prasinezumab reduces the worsening of motor symptoms in people with Parkinson's disease who have rapidly progressive disease, according to an analysis of a phase 2 clinical trial published in Nature Medicine. These findings suggest that clinical efficacy of prasinezumab, which works by binding to alpha-synuclein protein aggregates, is seen after one year of treatment in such patients. According to the authors, more research is needed to determine whether the antibody can be effective in people with slower disease progression after longer periods of treatment.